GSK Plc plans to buy back £2 billion ($2.5 billion) of shares as it raised its long-term growth outlook on optimism around ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

GSK (GSK) provides its full-year guidance at constant exchange rates; Turnover is expected to increase between 3% to 5%. Core operating profit ...

GSK acquires IDRx for $1 billion upfront, with $150M milestone payments; gains lead molecule IDRX-42 for gastrointestinal stromal tumors. IDRX-42 shows 53% ORR in 1 prior therapy line, targeting ...

GSK's annual revenues were held back weak vaccines sales, but shares in the pharma giant jumped on Wednesday after the ...

GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...

and certainly a lot stronger than what you see with the second-, third- and fourth-line drugs,” the CCO said. The deal is a continuation of GSK’s M&A strategy: acquiring assets designed to ...

Under the agreement, GSK will pay $1 billion upfront ... a highly selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. GIST typically presents in ...

GSK said pretax profit in 2024 fell 43% to GBP3.48 billion from GBP6.06 billion a year prior, though revenue increased 3.5% to GBP31.38 billion from GBP30.33 billion, ahead of the GBP31.05 billion ...

GSK (GSK) and IDRx announced that they have entered ... a selective KIT TKI being developed as a first- and second-line therapy for the treatment of GIST. IDRX-42 has demonstrated activity against ...